Table 1 Baseline characteristics of the study population by the two pre-specified groups
Metformin group N = 20 | Vildagliptin + metformin group N = 37 | p value | |
|---|---|---|---|
Age (years) | 68 ± 9 | 66 ± 9 | 0.85 |
Male gender | 12 (60%) | 31 (84%) | 0.11 |
BMI | 28 ± 4 | 28 ± 4 | 0.68 |
Past myocardial infarction | 11 (55%) | 22 (59%) | 0.77 |
Status post CABG | 7 (35%) | 7 (20%) | 0.28 |
Hypertension | 16 (80%) | 28 (77%) | 0.77 |
TIA | 2 (10%) | 3 (8%) | 0.58 |
Left ventricular EF | 52 ± 10 | 53 ± 11 | 0.56 |
NYHA class ≥III | 3 (15%) | 9 (23%) | 0.76 |
past valve repair/replacement | 1 (5%) | 1 (2.6%) | 0.76 |
ACE inhibitors | 12 (60%) | 22 (59%) | 0.94 |
ARBs | 2 (10%) | 10 (26%) | 0.16 |
ß Blockers | 17 (85%) | 27 (74%) | 0.35 |
Calcium channel blockers | 5 (25%) | 6 (16%) | 0.37 |
Statins | 19 (95%) | 37 (100%) | 0.63 |
Fasting glucose | 139 ± 31 | 147 ± 50 | 0.71 |
AST | 22 ± 7 | 28 ± 12 | 0.10 |
ALT | 22 ± 8 | 29 ± 12 | 0.16 |
HDL | 39 ± 7 | 41 ± 9 | 0.63 |
LDL | 75 ± 20 | 76 ± 30 | 0.35 |
Triglycerides | 176 ± 95 | 124 ± 41 | 0.001 |
HbA1c | 7.3 ± 0.6 | 7.1 ± 0.5 | 0.63 |
IL-1 beta | 37.5 ± 24 | 34.5 ± 11 | 0.58 |
IL-6 | 8.4 ± 5.5 | 6.7 ± 2 | 0.11 |
IL-10 | 8.2 ± 1 | 11.9 ± 3 | 0.22 |
TNF-alpha | 15.6 ± 4.4 | 14.2 ± 2.5 | 0.12 |
MCP-1 | 180 ± 38 | 173 ± 43 | 0.58 |
Matrix metallo-proteinase 9 | 60,355 ± 2519 | 61,343 ± 17,181 | 0.82 |